DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm
The owner of DIAGOMICS has sold the company to ZytoMax GmbH.
Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.
Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.
Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.
Gwénola Tanneau
Founder and CEO, DIAGOMICS
Talk to the deal team
Related deals
Sun European Partners has secured financing to support its acquisition of B&H Worldwide
Sun European Partners has raised debt facilities to support its acquisition of B&H Worldwide.
Learn moreParcom has sold Krifon to Varro
Krifon AS, a leading Nordic B2B distributor specializing in home and garden products, has been acquired by Varro. The transaction marks a new chapter for the company as it continues to strengthen its position as a trusted category partner to leading DIY chains, garden centers and furniture retailers in Norway.
Learn moreEbidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment
Ebidco S.r.l. has completed a voluntary public tender offer for the shares of Eles Semiconductor Equipment S.p.A.
Learn more